RETRACTED: Meta-analysis:: the relationship between Helicobacter pylori infection and gastro-oesophageal reflux disease (Retracted Article. See vol 19, p 145, 2004)

被引:70
作者
Cremonini, F
Di Caro, S
Delgado-Aros, S
Sepulveda, A
Gasbarrini, G
Gasbarrini, A
Camilleri, M
机构
[1] Mayo Clin & Mayo Fdn, Clin Enter Neurosci Translat & Epidemiol Res Prog, Rochester, MN 55902 USA
[2] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA
[3] Gemelli Hosp, Rome, Italy
关键词
D O I
10.1046/j.1365-2036.2003.01665.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: The relationship between Helicobacter pylori infection and its treatment and gastro-oesophageal reflux disease (GERD) is controversial. Aims: To establish if H. pylori infection is associated with the presence of GERD and if anti-H. pylori treatment leads to de novo GERD or rebound/exacerbation of GERD. Methods: A search of MEDLINE and EMBASE databases was made. Pooled odds ratios (OR) were calculated for de novo GERD and rebound/exacerbated GERD after anti-H. pylori therapy in case-control studies and in therapeutic trials. Results: Fourteen case-control studies and 10 clinical trials were included. Among case-control studies, pooled OR for the association between H. pylori negative status and GERD was 1.34 [95% confidence interval (CI) 1.15-1.55]. Among therapeutic trials, pooled OR for the association anti-H. pylori therapy - GERD was 2.54 (95% CI 1.92-3.37). The OR for de novo GERD was 3.25 (95% CI 2.09-5.33), and for rebound/exacerbated GERD was 2.39 (95% CI 1.75-3.34). Associations were higher among Asian studies than among North American and European studies. Conclusions: This meta-analysis shows significant association between absence of H. pylori infection and GERD symptoms, and a positive association between anti-H. pylori therapy and occurrence of both de novo and rebound/exacerbated GERD. The significance of these associations appears to have been inflated by the effect of single trials and by geographical variations.
引用
收藏
页码:279 / 289
页数:11
相关论文
共 53 条
  • [1] Relapse prevention in reflux oesophagitis with regard to Helicobacter pylori status:: a double-blind, randomized, multicentre trial to compare the efficacy of pantoprazole versus ranitidine
    Adamek, RJ
    Behrendt, J
    Wenzel, C
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2001, 13 (07) : 811 - 817
  • [2] Curing Helicobacter pylori infection in patients with duodenal ulcer does not provoke gastroesophageal reflux disease
    Befrits, R
    Sjöstedt, S
    Ödman, B
    Sörngård, H
    Lindberg, G
    [J]. HELICOBACTER, 2000, 5 (04) : 202 - 205
  • [3] Boixeda D, 1995, MED CLIN-BARCELONA, V105, P774
  • [4] How does Helicobacter pylori cause mucosal damage? Its effect on acid and gastrin physiology
    Calam, J
    Gibbons, A
    Healey, ZV
    Bliss, P
    Arebi, N
    [J]. GASTROENTEROLOGY, 1997, 113 (06) : S43 - S49
  • [5] PREVALENCE OF CAMPYLOBACTER-PYLORI IN ESOPHAGITIS, GASTRITIS, AND DUODENAL DISEASE
    CHENG, EH
    BERMANSKI, P
    SILVERSMITH, M
    VALENSTEIN, P
    KAWANISHI, H
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1989, 149 (06) : 1373 - 1375
  • [6] Csendes A, 1997, Dis Esophagus, V10, P38
  • [7] Bias in meta-analysis detected by a simple, graphical test
    Egger, M
    Smith, GD
    Schneider, M
    Minder, C
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1997, 315 (7109): : 629 - 634
  • [8] Opposing time trends of peptic ulcer and reflux disease
    El-Serag, HB
    Sonnenberg, A
    [J]. GUT, 1998, 43 (03) : 327 - 333
  • [9] Corpus gastritis is protective against reflux oesophagitis
    El-Serag, HB
    Sonnenberg, A
    Jamal, MM
    Inadomi, JM
    Crooks, LA
    Feddersen, RM
    [J]. GUT, 1999, 45 (02) : 181 - 185
  • [10] Helicobacter pylori infection and chronic gastric acid hyposecretion
    ElOmar, EM
    Oien, K
    ElNujumi, A
    Gillen, D
    Wirz, A
    Dahill, S
    Williams, C
    Ardill, JES
    McColl, KEL
    [J]. GASTROENTEROLOGY, 1997, 113 (01) : 15 - 24